Congress won’t include PhRMA-backed Medicare change in opioids package
PhRMA’s been trying all year to get Congress to relieve the industry of some of its responsibility for certain Medicare drug costs. It just lost again.
WASHINGTON — The latest version of a bill to address the opioid crisis will not include an unrelated, drug industry-backed provision that would relieve drug companies of some of their responsibility for certain Medicare drug costs, multiple lobbyists with knowledge of the bill told STAT.
The bill also will not include any version of the CREATES Act, a long-stalled bill to incentivize the production of cheaper generic and biosimilar drugs.
The opioids legislation, which
